August 23, 2022 – The Oncology Institute, one of the largest value-based community oncology groups in the United States, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, have partnered to provide enhanced psychological support services for TOI patients.
Blue Note’s cancer-specific prescription digital therapeutic attune™ is the first digital therapeutic designed to treat anxiety and depression symptoms related to cancer. Attune will be available to all eligible TOI patients by prescription.
“As community-based providers, TOI teammates work closely with patients and their families to connect them to resources that help them navigate their cancer journey,” shared Dr. Daniel Virnich, TOI’s President. “We are excited to offer attune to patients coping with cancer-related psychological distress as part of our larger patient-centric, value-based care model.”
“Diagnosis and treatment of cancer can cause an enormous amount of stress that is both normal and expected. Blue Note is committed to helping patients find constructive ways to cope,” said Geoffrey Eich, CEO, Blue Note Therapeutics. “Offering attune to patients in TOI clinic locations will expand access to cancer-specific mental health care, meeting a need for the 85 percent of all cancer patients in the U.S. treated in a community setting.”
Blue Note developed attune as an “on-demand” self-directed tool for patients with cancer. Attune takes cancer-specific face-to-face therapies, backed by decades of evidence-based research, and re-creates that experience in a digital format on the patient’s mobile device. Attune includes a virtual and asynchronous patient support group feature which allows patients to support each other from a time and place of their choosing.